Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 3/20 | 0.46 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.46 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.46 |
| ▸ | CDK8 | P49336 | 1/20 | 0.46 |
| ▸ | CLK2 | P49760 | 1/20 | 0.46 |
| ▸ | CDK7 | P50613 | 1/20 | 0.46 |
| ▸ | CDK9 | P50750 | 1/20 | 0.46 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.46 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.46 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.46 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.46 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL163889 | 0.84 | MAP4K4 (0.54) | DYRK1ADYRK1BMAP4K4CDK8CLK2 | |
| SCHEMBL3371454 | 0.84 | ESR2 (0.59) | DYRK1ADYRK1BMEN1KMT2AKDM4E | |
| SCHEMBL20528292 | 0.83 | BACE1 (0.47) | DYRK1AMEN1KMT2AKDM4EMAPT | |
| SCHEMBL5509853 | 0.76 | ALDH1A1 (0.50) | DYRK1AMEN1KMT2AMAPTHTT | |
| SCHEMBL6438602 | 0.76 | DYRK1A (0.37) | DYRK1ADYRK1BMAP4K4CDK8CLK2 | |
| SCHEMBL584342 | 0.76 | BACE1 (0.41) | DYRK1AKMT2AKDM4EHPGDNPC1 | |
| SCHEMBL622744 | 0.76 | EGFR (0.53) | DYRK1ADYRK1BROCK1MEN1KMT2A | |
| SCHEMBL16289378 | 0.76 | MAP4K4 (0.46) | DYRK1ADYRK1BMAP4K4CDK8CLK2 | |
| SCHEMBL789944 | 0.76 | PDGFRB (0.39) | DYRK1AHPGDPDGFRBPDGFRAPDE3B | |
| SCHEMBL5537413 | 0.76 | CYP1A2 (0.57) | DYRK1ADYRK1BMAP4K4CDK8CLK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 134 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12577258-B2 | Macrocyclic compound | VERNALIS (R&D) LIMITED (GB) | 2026-03-17 | — | — | US | disclosed |
| WO-2025227032-A1 | METHODS FOR DEGRADATION OF CYCLIN K AND INHIBITION OF CYCLIN DEPENDENT KINASES | REMIX THERAPEUTICS INC. (US) | 2025-10-30 | — | — | WO | disclosed |
| US-12441708-B2 | Cereblon ligands and bifunctional compounds comprising the same | ARVINAS OPERATIONS, INC. (US) | 2025-10-14 | — | — | US | disclosed |
| US-20250313547-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | ARVINAS OPERATIONS INC (US) | 2025-10-09 | — | — | US | disclosed |
| EP-4626870-A1 | NONCOVALENT KEAP1-NRF2 SMALL-MOLECULE INHIBITORS | University of Copenhagen (DK) | 2025-10-08 | — | — | EP | disclosed |
| EP-4223368-B1 | MACROCYCLIC COMPOUNDS INCORPORATING PIPERIDINE AND QUINOLINE OR QUNAXOLINE AS IRAK-4 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY CONDITIONS | ASAHI KASEI PHARMA CORP (JP) | 2025-05-21 | — | — | EP | disclosed |
| CN-116348472-B | Macrocyclic compounds | 旭化成制药株式会社 | 2024-12-03 | — | — | CN | disclosed |
| CN-118525020-A | Compound with CLK and DYRK inhibiting activity, preparation method and application thereof | 赛诺哈勃药业（成都）有限公司 | 2024-08-20 | — | — | CN | disclosed |
| WO-2024115641-A1 | NONCOVALENT KEAP1-NRF2 SMALL-MOLECULE INHIBITORS | UNIVERSITY OF COPENHAGEN (DK) | 2024-06-06 | — | — | WO | disclosed |
| US-20240132431-A1 | METHOD FOR ALKYLATING ACIDIC FUNCTIONAL GROUP | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-04-25 | — | — | US | disclosed |
| EP-0929563-B1 | 6-O-SUBSTITUTED KETOLIDES HAVING ANTIBACTERIAL ACTIVITY | ABBOTT LAB (US) | 2005-06-01 | — | — | EP | disclosed |
| EP-1291352-B1 | 6-O-substituted ketolides having antibacterial activity | ABBOTT LAB (US) | 2005-05-25 | — | — | EP | disclosed |
| EP-1291350-B1 | 6-0 substituted ketolides having antibacterial activity | ABBOTT LAB (US) | 2005-05-25 | — | — | EP | disclosed |
| WO-2004108663-A1 | N-ALKYNYL-2- (SUBSTITUTED ARYLOXY) ALKYLTHIOAMIDE DERIVATIVES AS FUNGICIDES | SYNGENTA LIMITED (GB) | 2004-12-16 | — | — | WO | disclosed |
| WO-2004047538-A1 | QUINOLIN-, ISOQUINOLIN-, AND QUINAZOLIN-OXYALKYLAMIDES AND THEIR USE AS FUNGICIDES | SYNGENTA LIMITED (GB) | 2004-06-10 | — | — | WO | disclosed |
| EP-1291352-A1 | 6-O-substituted ketolides having antibacterial activity | ABBOTT LABORATORIES (US) | 2003-03-12 | — | — | EP | disclosed |
| EP-1291353-A1 | 6-O-substituted ketolides having antibacterial activity | ABBOTT LABORATORIES (US) | 2003-03-12 | — | — | EP | disclosed |
| EP-1291350-A1 | 6-0 substituted ketolides having antibacterial activity | ABBOTT LABORATORIES (US) | 2003-03-12 | — | — | EP | disclosed |
| EP-1291351-A1 | 6-0 substituted ketolides having antibacterial activity | ABBOTT LABORATORIES (US) | 2003-03-12 | — | — | EP | disclosed |
| CN-1237183-A | 6-0-substituted ketolides with antibacterial activity | ABBOTT CO (US) | 1999-12-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12577258-B2 | Macrocyclic compound | IRAK1, IRAK4, IRAK2 | DYRK1A 4367/4885DYRK1B 4526/4885MAP4K4 1271/4885 |
| US-20250313547-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | CRBN, CBL, MDM2 | DYRK1A 849/4885DYRK1B 880/4885MAP4K4 3966/4885 |
| US-20240132431-A1 | METHOD FOR ALKYLATING ACIDIC FUNCTIONAL GROUP | MGMT, MCL1, FANCF | DYRK1A 4636/4885DYRK1B 4658/4885MAP4K4 2614/4885 |
| US-12441708-B2 | Cereblon ligands and bifunctional compounds comprising the same | CRBN, CBL, MDM2 | DYRK1A 849/4885DYRK1B 880/4885MAP4K4 3966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.